Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
Times cited: 66
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Breast cancer research : BCR.
Times cited: 102